Please try another search
Aileron Therapeutics, Inc. is a clinical-stage chemoprotection oncology company. It is focused on developing medicines to make chemotherapy safer. Its ALRN-6924 product is a MDM2/MDMX dual inhibitor that leverages its peptide drug technology, which is designed to activate p53, which in turn upregulates p21, a known inhibitor of the cell replication cycle. ALRN-6924 is the chemoprotective agent in clinical development, which focused on treating patients with p53-mutated cancers. It is developing ALRN-6924 to selectively protect healthy cells in patients with cancers that harbor p53 mutations to reduce or eliminate chemotherapy-induced side effects without interrupting chemotherapy’s destruction of cancer cells. It stabilizes peptides by stapling them with hydrocarbon bonds into their natural alpha-helical conformation. ALRN-6924 can pause cell division in cells with wild type, p53, include normal bone marrow cells and ALRN-6924 has no activity against cancer cells with mutations in p53.
Name | Age | Since | Title |
---|---|---|---|
Reinhard J. Ambros | 69 | 2013 | Independent Lead Director |
William Carl Fairey | 59 | 2023 | Independent Director |
Josef H. von Rickenbach | 69 | 2019 | Independent Chairman |
Alan A. Musso | 62 | 2023 | Independent Director |
Manuel C. Aivado | 54 | 2014 | Director |
Alan F. List | 69 | 2018 | Member of Scientific Advisory Board |
Carol L. Prives | - | 2018 | Member of Scientific Advisory Board |
Ulrich Steidl | - | - | Member of Scientific Advisory Board |
Brian J. Druker | 69 | 2018 | Member of Scientific Advisory Board |
James Brian Windsor | 57 | 2023 | CEO & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review